An optical method for reducing green fluorescence from urine during fluorescence-guided cystoscopy by Lindvold, Lars René & Hermann, Gregers G
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners 
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
• You may not further distribute the material or use it for any profit-making activity or commercial gain 
• You may freely distribute the URL identifying the publication in the public portal  
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
   
 
Downloaded from orbit.dtu.dk on: Dec 18, 2017
An optical method for reducing green fluorescence from urine during fluorescence-
guided cystoscopy
Lindvold, Lars René; Hermann, Gregers G
Published in:
Methods and Applications in Fluorescence
Link to article, DOI:
10.1088/2050-6120/4/4/045002
Publication date:
2016
Document Version
Peer reviewed version
Link back to DTU Orbit
Citation (APA):
Lindvold, L. R., & Hermann, G. G. (2016). An optical method for reducing green fluorescence from urine during
fluorescence-guided cystoscopy. Methods and Applications in Fluorescence, 4(4), [045002]. DOI: 10.1088/2050-
6120/4/4/045002
An optical method for reducing green 
fluorescence from urine during fluorescence-
guided cystoscopy 
 
 
Lars R Lindvold1 and Gregers G Hermann2 
 
1DTU Centre for Nuclear Technologies (NUTECH), Technical University of Denmark, Risø Campus, DK 4000 
Roskilde, Denmark 
 2Urological Research Unit, Urology Department, Herlev/Gentofte hospital, DK 2900 Hellerup, Denmark 
 
lali@dtu.dk 
Abstract: Photodynamic diagnosis (PDD) of bladder tumour tissue significantly 
improves endoscopic diagnosis and treatment of bladder cancer in rigid 
cystoscopes in the operating theatre and thus reduces tumour recurrence. PDD 
comprises the use of blue light, which unfortunately excites green fluorescence 
from urine. As this green fluorescence confounds the desired red fluorescence of 
the PDD, methods for avoiding this situation particularly in cystoscopy using 
flexible cystoscopes are desirable. In this paper we demonstrate how a tailor made 
high power LED light source at 525 nm can be used for fluorescence assisted 
tumour detection using both a flexible and rigid cystoscope used in the outpatient 
department (OPD) and operating room (OR) respectively. It is demonstrated both 
in vitro and in vivo how this light source can significantly reduce the green 
fluorescence problem with urine. At the same time this light source also is useful 
for exciting autofluorescence in healthy bladder mucosa. This autofluorescence 
then provides a contrast to the sensitized fluorescence (PDD) of tumours in the 
bladder.      
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1. Introduction 
According to a recently published review article on bladder cancer (Antoni et al 
2016), this cancer form accounted for almost 430.000 new cases diagnosed in 
2012 worldwide. A further look into the numbers related to bladder cancer found 
on the homepage of the International Agency for Research on Cancer reveals that 
more men than women are affected by this disease. The numbers worldwide are 
found in table 1 below. 
 
Table 1. Worldwide incidence, mortality and 5 year prevalence of bladder cancer 
in men and women according to GLOBOCAN 2012 v1.0, cancer incidence and 
mortality worldwide (http://globocan.iarc.fr/Pages/fact_sheets_population.aspx).   
 
 Men  Women 
Incidence 330,380 99,413 
Mortality 123,051 42,033 
5 Year prevalence 1,018,415 301,334 
 
 
One of the most common surgical procedures for eradicating bladder tumours is 
transurethral resection of bladder tumours (TUR-B). This is an endoscopic 
procedure recommended in the European guidelines for treatment of bladder 
cancer (Babjuk et al 2011).  Fluorescence guided cystoscopy of the bladder is an 
integral part of TUR-B for identifying tumours in the bladder but also as a 
subsequent follow-up procedure (Hermann et al 2011). The fluorescence guided 
cystoscopy, also known as photodynamic diagnosis (PDD), is based on 
administration of an aqueous solution of an amino acid, hexylaminolevulinic acid 
(HAL), to the bladder through a catheter inserted in the urethra of the patient prior 
to TUR-B. The tumour cells convert this amino acid into a fluorescent substance 
Protoporphyrin IX (PpIX) (Krieg et al 2000). This dye has a characteristic red 
fluorescence centred at 635 nm which differs spectrally from the autofluorescence 
of the healthy bladder tissue (Bulgakova et al 2009). The advantage of PDD over 
conventional white-light cystoscopy (WLC) is its higher specificity, particularly 
towards low-grade tumours (Kausch et al 2010). HAL is preferred over 5-
aminolevulinic acid (5-ALA) due to its higher uptake by bladder tumour cells 
(Jocham et al 2008).      
To provide the surgeon with suitable excitation light, a light source with two 
illumination modes is used; blue light 430 nm (50 nm FWHM) and white light 
(400 nm to 700 nm). The blue light mode is intended to reveal the location of the 
bladder tumours through excitation of a strong red fluorescence, whereas the 
white light is used for general observation of the bladder mucosa by the surgeon. 
The most predominant type of light sources used in the clinic are Karl Storz (D-
Light) and Olympus EXERA II CLV 180.  
However, urine contains fluorescent metabolites, typically riboflavines (Lovisa et 
al 2010, Leiner et al 1987), which are excited to emit green fluorescence by the 
blue light used in PDD. The green fluorescence, as shown in figure 1, from these 
metabolites makes it impossible for the urologist to see details in the bladder. 
This impairs the use of PDD with flexible cystoscopes in the outpatient 
department (OPD). The green colour problem is limited in the operating room 
(OR) because green fluorescent metabolites from the urine are diluted by 
continuous bladder irrigation used in the OR.  Bladder irrigation is possible in the 
thick rigid cystoscopes used in the OR setting, but limited in the small flexible 
endoscopes used in the OPD.    
 
 
 Figure 1. Three images of green fluorescence from urine excited by blue light 
(430 nm) observed in a flexible cystoscope in the OPD , showing the increased 
obscuration of the view of the bladder wall as the urine enters the bladder from 
the kidney over an interval of 0, 5 and 10 seconds.  © Gregers G. Hermann. 
 
A previous study (Hermann et al 2012) has shown that histological diagnosis of 
non-muscle invasive bladder cancer (NMIBC) in biopsies obtained during 
flexible cystoscopy in the OPD in local anaesthesia, is as good as biopsies 
obtained through rigid cystoscopes the OR from patients in general anaesthesia 
(which is commonly regarded as the ‘gold standard’ for this purpose). There is 
therefore an impetus to move approximately 20% of patients with NMIBC from 
the OR to the OPD, which is faster, less resource-intensive, and works better for 
the patient and the healthcare system.  
 
In this paper we describe the in vivo use of a high-power LED light source for 
PDD developed at our laboratory, which reduces the green fluorescence of urine 
significantly. Using this light source, only one wavelength (525nm) is required to 
excite the red fluorescence of tumours and concomitant autofluorescence of the 
bladder. In conventional PDD, the surgeon has to switch between blue and white 
light to perform diagnosis and surgery respectively. The procedures are carried 
out with rigid cystoscope in the operating room (OR) and with a flexible 
cystoscope in the outpatient department (OPD). The proof of principle presented 
in this paper was done using commercially available cystoscopes and light guides. 
Due to the delicate nature of inserting surgical instruments, e.g., a cystoscope, 
into the human bladder, only certified equipment can be used. Furthermore, the 
use of commercially available instruments allows us to follow the European 
guidelines (Babjuk et al 2011) for transurethral resection of bladder tumours 
(TUR-B). 
 
2. Materials and Methods 
2.1 Preparation of Protoporphyrin IX (PpIX) for fluorescence measurements in 
vitro 
 
60.6 mg of Protoporphyrin IX disodium salt (equivalent of 0.100 mmol) were 
dissolved a phosphate buffered saline solution (PBS) to make a total volume of 
100 ml in a volumetric flask containing 1.00 ml Triton X-100 as surfactant to 
prevent agglomeration of the PpIX molecules, making up a 1.00 mM solution.  
This solution was further diluted by PBS containing 1% Triton-X to a 100 µM 
solution for measuring the absorption and fluorescence spectra respectively. 
The Protoporphyrin IX disodium salt was supplied by Sigma Aldrich# 258385, 
(Sigma-Aldrich Denmark A/S, Vallensbæk, Denmark). Triton X-100 used was 
Sigma Aldrich# X-100, (Sigma-Aldrich Denmark A/S, Vallensbæk, Denmark). 
Phosphate buffered saline (PBS) solution was made by dissolving a package of 
pre-mixed buffer from Sigma-Aldrich# P5368 water (Sigma-Aldrich Denmark 
A/S, Vallensbæk, Denmark)  in a 1000 ml volumetric flask using MilliQ water). 
The pH of the PBS was 7.4. 
 
2.2 Administration of Protoporphyrin IX in vivo 
 
In fluorescence-guided cystoscopy of the bladder, also known as photodynamic 
diagnosis (PDD), a 50 ml solution of a photosensitiser precursor, the hexyl 
derivative of 5-aminolevulininc acid (Hexvix®, Photocure ASA, Oslo, Norway), 
is administered to the bladder through a catheter via the urethra. This substance is 
metabolised in the mitochondria of the tumour cells to Protoporphyrin IX (PpIX) 
as a part of the heme cycle (Hamblin and Mróz ). PpIX emits red fluorescence 
(635 nm), making the tumours of the bladder fluoresce red when the bladder is 
illuminated by blue light (430 nm) through the cystoscope. 
 
2.3 The LED light source 
To match the optical power required for the cystoscope, a tailor-made LED-based 
light source has been developed in our laboratory. Only the light source is tailor-
made but with a light guide connection identical to that used in fluorescence 
assisted cystoscopy (PDD). Consequently, a user familiar with conventional 
photodynamic diagnosis of bladder tumours will immediately be able to use the 
new light source 
A detailed description of this light source can be found in a previous publication 
(Lindvold and Hermann 2015). In short, this light source is based on high power 
Luminus Devices PT-121-TE with a centre wavelength of 525 nm. Connected to 
a Storz 495NCS light guide, an optical output power density of 1.6 W/cm2 can be 
obtained before it is coupled to the cystoscope optics. It should be noted that the 
high power density is required to compensate for the insertion loss of almost 90% 
between the output of the light guide and the cystoscope optics. The spectral 
bandwidth of the light source is limited by a Semrock Brightline 525-25 bandpass 
filter. The bandpass filter serves two purposes, as shown in figure 2. One is to cut 
off any blue light from the LED that could excite green fluorescence from the 
urine and cause bleaching of the photosensitiser PpIX. The other is to prevent 
residual yellow and red light from the LED to enter the bladder as this would 
confound the autofluorescence of the bladder mucosa and the sensitised red 
fluorescence from the tumours.   
 Figure 2. The emission spectrum of 525 nm LED PT-121-TE from Luminus 
Devices without bandpass filter and with a Semrock Brightline 525-25 filter with 
a bandwidth (FWHM) of 25 nm.  
 
 
2.4 Spectrometers and power meter 
The absorption spectrum of urine was recorded using a UV-2700 double-beam 
spectrophotometer (Shimadzu, Holm & Halby, Denmark). The fluorescence 
spectra of PpIX and urine were measured using a Fluorolog 3 spectrofluorometer 
(Horiba Jobin Yvon, Longjumeau, France). PpIX samples prepared as described 
in section 2.1 were placed in a suitable fluorescence cuvette in the 
spectrofluorometer and measured in right-angle geometry. The spectral output of 
the high-power LED light source was measured using a QE65000 CCD 
spectrograph from Ocean Optics (Dunedin, FL, USA). The power density of the 
light source was measured using a PM100USB power meter fitted with a S120VC 
photodiode power sensor both from Thorlabs (Thorlabs AB, Gothenburg, 
Sweden). To prevent saturation of spectrometer and power meter, a reflective 
neutral density filter ND with an optical density of 4 was used from Thorlabs 
(Thorlabs AB, Gothenburg, Sweden). 
 
2.5 Optical components used in the experiment 
 
As this proof-of-principle is based on commercially available cystoscope 
instrumentation, no alterations can be made to the hardware. In particular, this 
means that the filter for blocking the reflected excitation light transmitted by the 
cystoscope from the bladder cavity cannot be incorporated in either the 
cystoscope (22 French cystoscope, Karl Storz, Tüttlingen, Germany) or the 
attached camera (Tricam Storz, Tüttlingen, Germany). 
It has previously been reported (Gahlen et al 2000) how the use of a longpass 
optical colour filter in the eyepiece of the cystoscope is required to block the 
excitation light of the cystoscope light source. The purpose of this filter is to 
enhance the sensitised fluorescence of the tumours and autofluorescence of the 
healthy tissue of the bladder mucosa. 
Such filters come in two generically different versions. One is based on 
interference filter technology and is often referred to as an edge filter. The others 
are based on absorption colour filters such as those supplied by Schott and Hoya. 
It is our experience that a blocking filter based on a thin film interference coating 
used in the eyepiece of a cystoscope suffers a serious drawback: As the 
cystoscope images objects with a distance from the distal end of the cystoscope 
ranging from 1 to 10 cm, an interference based bandpass filter will have light 
entering at very differing angles. In the case of an interference filter this will 
cause a different bandpass over the aperture of the eyepiece. This is not desirable 
in a fluorescence imaging setup. 
A colour filter based on absorption like a Schott or Hoya filter on the other 
hand would provide the imaging system with angular independent bandpass over 
the entire aperture when placed in the eyepiece of the cystoscope. In our 
experiments, a Hoya OG56 filter (diameter 12.5 mm and 2 mm thickness) was 
placed in the eyepiece of the cystoscope before the Storz Tricam was attached to 
the eyepiece. The Storz Tricam was operated in the PDD mode. In this mode 
exposure time of the CCD camera typically is set at 1/15 second. 
 
3. Results and discussion  
3.1 Spectral measurements of urine and Protoporphyrin IX  
Urine exhibits strong fluorescence in the blue-green spectral range when excited 
with blue light of commercially available endoscopic systems for photodynamic 
diagnosis. In order to assess the wavelength range that will excite the metabolites 
of urine, the absorption spectrum of urine was recorded using a Cary100 
spectrophotometer as shown in figure 3.  
 
Figure 3. VIS Absorption spectrum of urine in a 10 mm disposable plastic 
cuvette measured in double beam UV 2700 spectrophotometer with a 10 mm 
OS cuvette containing MilliQ water in the reference beam. 
 
It should be noted that the amplitude of the absorption spectrum of human urine 
varies from person to person. The spectral signature, however, is the same. This 
means that the spectrum shown in figure 3 is representative for people without 
unusual medical conditions like porphyria (Castrow et al 1968).  
Figure 3 shows that light (430nm centre wavelength) of commercial available 
PDD systems, is strongly absorbed by urine (50% at 430 nm) and will cause the 
urine to fluoresce, but light with wavelengths above 500 nm  are  only absorbed 
marginally (10% at 525 nm) by urine in a 10 mm cuvette. It is, however, worth 
mentioning that the optical path length of the bladder is significantly larger than 
10 mm due to fact that the urine is excited in backscattered fluorescence geometry 
rather than simple transmission geometry, the total optical path length more likely 
is 200 mm in the worst case and 50mm to 100 mm under clinical observation 
conditions.  Assuming the absorbance to follow the Beer-Lambert law, further 
increasing the optical path length causes an even greater absorbance of the blue 
excitation light and hence a much stronger fluorescence signal from urine can be 
expected at 430 nm than 525 nm. The bladder can be regarded as a cuvette during 
cystoscopic procedures as it is inflated by water to allow a full view of its surface 
by the surgeon.    
It should be noted that absorption by a metabolite does not necessarily lead to 
fluorescence per se. Based on the work of other groups (Lovisa et al 2010) and 
(Leiner et al 1987), however, similar absorption spectra have been recorded and 
correlated to the fluorescence of urine. Previously published methods for 
suppressing this green fluorescence have only reported results made in vitro 
(Lovisa et al  2010).  
The results of the fluorescence measurements shown in figure 4 demonstrate a 
correlation between light absorption in urine and the magnitude of fluorescence of 
urine and PpIX respectively.  
 
Figure 4. Fluorescence spectra of urine measured in right-angle geometry in 
disposable plastic fluorescence cuvettes with optical path length 10 mm measured 
at 430 nm and 525 nm excitation wavelengths respectively. 
 
It is, however, important to note that fluorescence spectra shown in figure 4 only 
reflect the spectral properties of urine in vitro. During PDD in a bladder, the 
intensity of green fluorescence of urine will completely confound that of PpIX as 
the path length of excited volume is more than an order of magnitude larger than 
that of the PpIX containing tumour. 
It can be inferred from figure 4 that 525 nm is beneficial for reducing the 
fluorescence of urine. The question, however, is whether it will be suitable for 
fluorescence excitation of PpIX? 
The spectrum recorded by a Shimadzu UV-2700 spectrophotometer shown in 
figure 5 reveals that PpIX possesses minor absorption peaks located in a spectral 
region where the spectral absorption of urine, as shown in figure 3, is known to be 
very small. 
 
 
 
 
Figure 5. Absorption spectrum of 100 µM Protoporphyrin IX di-sodium salt in 
PBS with 1% Triton X-100 recorded in OS cuvette with a path length of 10 mm 
and OS cuvette with a path length of 10 mm containing MilliQ water for 
reference. The absorption peaks have been located using the peak finder function 
of the UV-2700 spectrophotometer software. 
 
It could be argued that the decrease in absorption would lead to reduced 
fluorescence from PpIX. As the fluorescence spectrum of PpIX shows in figure 6 
this appears not to be the case. The spectra also demonstrate how the fluorescence 
of urine can be reduced by more than an order of magnitude using a longer 
wavelength for excitation of PpIX. As can be observed from the fluorescence 
spectrum of a 100 µM di-sodium PpIX PBS solution with 1% Triton X-100  
shown in figure 6, the fluorescence intensity of PpIX is not compromised by 
changing the excitation wavelength from 430 nm to 525 nm. An observation 
substantiated by the cystoscope picture in figure 7a, where the bright red 
fluorescence of bladder tumours can be observed clearly in vivo using the green 
LED light source developed in our laboratory. 
  
 
Figure 6. Fluorescence spectra of  a 100 µM PpIX-disodium salt in PBS with 1% 
Triton X-100 and urine at 525 nm excitation measured in disposable plastic 
fluorescence cuvettes with 10 mm path length. 
 
3.3 In vivo test of 525 nm excitation light for PDD of bladder tumours 
Based on the observations that the blue light from commercial PDD light sources 
cause significant green fluorescence in the bladder during PDD, a proof-of-
principle cystoscope set-up based on the green LED light source described in 
section 2.3 was implemented.  
For a proof-of-principle, 2 patients were selected for testing the efficacy of 
replacing the conventional light source in the OR and one patient in OPD by the 
new LED based light source emitting light at 525 nm. The patients were treated in 
accord to the Helsinki Declaration, the regulations of the local ethical committee, 
the Danish guide lines for treatment of bladder cancer, and had given informed 
consent before surgery. The patient in the OR had previously had a bladder 
tumour identified during endoscopy performed in the outpatient department. A 
Karl Storz PDD D-light system and Karl Storz endoscope for white light (not for 
blue light) was used (22 French cystoscope, Karl Storz, Tüttlingen, Germany) 
was used for the procedures in the OR. The patient in OPD was admitted for a 
follow-up on a TUR-B. 
In the beginning of the surgical procedure the cystoscope was introduced to the 
bladder in white light and the bladder examined in white light. Then the white 
light source was replaced with our 525 nm LED light source, and a Hoya OG56 
longpass filter was placed between the eyepiece of the cystoscope optics and the 
CCD-camera to allow observation of PpIX fluorescence from the tumours and the 
autofluorescence from the healthy bladder tissue. Fluorescence from the tumour 
was recorded at the same time as urine was observed in the bladder but without 
green colouring (figure 7a). Furthermore, it was found that a clear picture could 
be obtained of the bladder mucosa using only autofluorescence as shown in figure 
7b. It is noteworthy that the ostium is also visible in figure 1, before the bladder is 
filled with urine. During observation of this region in the cystoscope, using the 
LED light source at 525 nm, it could be observed that urine was flowing out of 
the ureter as the flow caused optical turbulence similar to that of a hot spring, but 
no green fluorescence due to the change in excitation wavelength.  
 
   
                                
 
(a)                                                      (b) 
 
Figure 7a and 7b. The pictures show that the LED light source presented in this 
article is capable of exciting both PpIX sensitised fluorescence of tumours (7a) in 
a bladder as well as autofluorescence of the bladder mucosa (7b) with urine 
present inside the bladder, without changing the wavelength of the cystoscope 
light source as would be the case in conventional systems for PDD of tumours in 
the bladder. In 7a the orange-red fluorescence caused by PpIX in the egg-shaped 
tumours with a size of 3-5 mm can be seen, covering most of the field of vision. 
The arrow in figure 7b points to healthy bladder mucosa with yellow auto 
fluorescence.  Both images recorded using a Storz rigid cystoscope with Storz 
Tricam® and Hoya OG56 filter in the eyepiece. © Gregers G. Hermann. 
 
It is important to realise that the use of the new LED-based light source enables 
the surgeon to observe the red fluorescence from tumours as well as auto-
fluorescence from healthy tissue, which is typically yellow with a slight green tint 
caused by a controlled leaking of excitation light through the rejection filter in the 
eyepiece of the cystoscope optics. Contrary to normal PDD procedures where the 
surgeon switches between two settings (blue light and white light), only one 
setting is required with the new 525 nm LED light source . 
To make a comparison between white light illumination of the bladder and 
autofluorescence (AF) imaging based on excitation with the 525 nm LED light 
source, two videos were recorded with the same patient. As can be seen in figure 
8 the image is still sharp, although in a different colour due to AF. The 
cauterizing probe in the picture indicates that surgery could be carried out using 
AF as the only illumination source. 
 
Ostium 
  
                                   (a)                                                                     (b) 
 
Figure 8a and 8b. The pictures show a part of a healthy bladder mucosa in 
conventional white light cystoscopy (8a) and using our green LED light source 
for exciting autofluorescence of the healthy bladder mucosa (8b). The use of a 
single green LED light source facilitates observation of the entire bladder mucosa 
using autofluorescence and tumours by sensitised fluorescence concomitantly. 
The surgeon will not have to switch between two lamp settings. The probe seen in 
both pictures is an electrically heated probe for cauterizing tumours. Both images 
were recorded using a Storz rigid cystoscope with Storz Tricam® and Hoya 
OG56 filter in the eyepiece. © Gregers G. Hermann. 
 
The last trial preformed was to test the hypothesis, that the LED light source 
could be used in a flexible cystoscope. The LED light source was tested with a 
patient who had been referred to the OPD for a follow-up cystoscopy.  
 
 
(a) 
 
(b) 
 
(c) 
 
 
Figure 9. The sequence of images shows (a) white light observation of bladder 
wall and flexible cystoscope optics (black tube), (b) the same scene now with blue 
light (430 nm) illumination for photodynamic diagnosis with distinct green urine 
fluorescence, and (c) the same scene with green LED illumination of the bladder. 
Note the absence of green fluorescence from urine that otherwise obscures the 
image as shown in 9b. All images were recorded using a Storz flexible cystoscope 
with Storz Tricam® and Hoya OG56 filter in the eyepiece © Gregers G. 
Hermann. 
 
The images shown in figure 9 demonstrate that the proposed concept of using 
green light in flexible cystoscopes in OPD is viable. The images obtained with the 
flexible cystoscope, however, were not of the same quality as the ones obtained 
by a rigid cystoscope. The quality, though, merely reflects that a good quality 
flexible cystoscope was not available on site at that time in the outpatient 
department.  
 
 
4. Conclusions 
We have shown in vivo that the ubiquitous problem of green fluorescence during 
PDD for bladder tumours, particularly when using flexible cystoscopes, can be 
circumvented by selecting excitation light in the green spectral range rather than 
blue spectral range currently used by the commercial systems.  It is noteworthy 
that the light source presented in this article is used with standard white-light 
cystoscopes and light guides, without any blue-light optics.  
Furthermore, it was also observed that using green excitation light also made it 
possible to use the autofluorescence of the mucous membrane in the bladder for 
general observation, provided that a suitable bandpass filter was placed in 
eyepiece of the endoscope optics. This may possibly replace the use of white light 
sources for general viewing during cystoscope based PDD procedures for removal 
of bladder tumours.  
It is important to emphasize, that the results presented in this paper are to be 
regarded as a proof-of-principle. Based on the observations reported in this paper, 
a series of experiments will be needed to prove the efficacy of the new method in 
order to establish a proper protocol for this method in the clinic, including a study 
of a larger cohort of patients. This will provide us with better statistical grounds 
for substantiating the advantages of the new method compared to conventional 
PDD with two illumination modes, i.e., blue for fluorescence excitation and white 
light for general observation. Another very important issue to be addressed in the 
future, if the proposed technique is translated from proof of principle to a new 
medical device, is the regulatory environment. Approval of the device will be 
mandatory; in the EU via CE marking and in the US via FDA approval.  
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